Pharmaceutical company Pfizer has come under fire for apparently failing to disclose research showing a drug used for treating rheumatoid arthritis may reduce the risk of Alzheimer’s disease by 64 per cent.

But would a company bury such significant research which could potentially benefit millions and make huge profits?

Professor John Mamo of Curtin University’s Health Innovation Research Institute takes us through this knotty issue.

Download this podcast here